H. Hayashi

Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: a secondary analysis from MARIPOSA

Enriqueta Felip, Byoung Chul Cho, Adlinda Alip et al. · Annals of Oncology · 2024 · 81 citations · Full text

Medicine, Oncology, Pharmacology +17

4O: Amivantamab plus lazertinib vs osimertinib in first-line (1L) EGFR-mutant (EGFRm) advanced NSCLC: Final overall survival (OS) from the phase III MARIPOSA study

J.C-H. Yang, Yoon Jun Kim, SH Lee et al. · Journal of Thoracic Oncology · 2025 · 44 citations · Full text

Medicine, Oncology, Pharmacology +11

LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA study

B. Besse, SH Lee, Shun Lü et al. · Annals of Oncology · 2024 · 42 citations · Full text

Medicine, Oncology, Pharmacology +17

1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

B.T. Li, David Planchard, Kōichi Goto et al. · Annals of Oncology · 2023 · 37 citations · Full text

Medicine, Oncology, Pharmacology +12

Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with oncogene-addicted metastatic non-small-cell lung cancer

Se‐Hoon Lee, Jessica Menis, T.M. Kim et al. · ESMO Open · 2024 · 18 citations · Full text

Medicine, Oncology, Cancer Control +10